<DOC>
	<DOCNO>NCT01897480</DOCNO>
	<brief_summary>The primary purpose study compare efficacy study drug LY2875358 , give together erlotinib , erlotinib , alone . Participants Non-Small Cell Lung Cancer ( NSCLC ) advance Stage IV . Participants treat drug Stage IV NSCLC , previously . All participant get erlotinib alone , approximately 8 week . Participants radiographic disease control end erlotinib lead-in study period randomly assign receive LY2875358 plus erlotinib erlotinib alone . Participants , choose receive erlotinib , alone , may cross combination treatment time progression .</brief_summary>
	<brief_title>A Study LY2875358 Participants With Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Histologically cytologically confirm diagnosis metastatic Stage IV NSCLC Have least 1 measurable lesion whose presence assessable use standard technique Response Evaluation Criteria Solid Tumors ( RECIST version 1.1 ) Have molecular evidence epidermal growth factor receptor mutation ( EGFRmt ) know associate EGFR tyrosine kinase inhibitor ( TKI ) drug sensitivity ( G719X , exon 19 deletion , L858R , L861Q ) Eastern Cooperative Oncology Group ( ECOG ) performance status â‰¤ 2 Have n't receive prior systemic chemotherapy Stage IV NSCLC ( unless receive neoadjuvant adjuvant therapy earlystage NSCLC disease complete therapy least 6 month prior enrollment ) Availability adequate tumor material ( block slide ) Are currently enrol , discontinue within last 30 day , clinical trial involve investigational product nonapproved use drug device Have previously complete withdrawn study study investigate LY2875358 Have serious concomitant systemic disorder significant cardiac disease Have interstitial pneumonia interstitial fibrosis lung pleural effusion , pericardial fluid ascites , require drainage every week frequently Have history another malignancy except basal squamous cell skin cancer and/or situ carcinoma cervix , solid tumor treat curatively without evidence recurrence least 3 year prior study Have major surgery le 2 week prior initiation study treatment therapy Pregnant lactating woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>